Apollomics Share Price

Apollomics Share Price

NASDAQ: APLMW | Others
$0.01
+0.00 (0.00%) Last updated on 14 Oct, 2026 | 19:34 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

Apollomics Stock Performance

Open
N/A
Prev. Close
$0.01
Circuit Range
N/A
Day Range
N/A
Year Range
$0.01 - $0.04
Volume
N/A
Average Traded
N/A

Apollomics Share Price Chart

$0.00$0.00
L
Show Current Price
H

Apollomics Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
N/A
EPS (TTM)
N/A
Revenue (TTM)
$8.50B
Return On Equity (TTM)
N/A
Profit Margin
-128.71%
Debt to Equity
N/A
Quarterly Earnings Growth YoY
N/A

Apollomics Annual Profit & Loss

All figures in USD

Particulars202320242025
Revenue$0.00$0.00$8.50
Net Profit-$172.60-$53.86-$10.94
Net Profit MarginN/AN/A-128.71%
Income ChangeN/A68.79%79.69%

Apollomics Balance Sheet

All figures in USD Million

Particulars202520242023
Non Current Assets0.662.8315.46
Current Assets6.0510.2739.93
Total Assets6.7113.155.39
Non Current Liabilities3.580.840.6
Current Liabilities6.337.413.56
Total Liabilities9.98.2314.15
Shareholders' Equity-3.194.8641.23

Apollomics Cash Flow

Annually

All figures in USD Million

Particulars202520242023
Operating-10.37-28.74-43.21
Investing0.225.9821.37
Financing3.680.4721.23

About Apollomics

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.

Apollomics Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$0.01
$0.01
-9.09%
Sep 2026
$0.01
$0.01
-21.43%
Aug 2026
$0.02
$0.01
-30.00%
Jul 2026
$0.02
$0.02
-13.04%
Jun 2026
$0.02
$0.02
+76.92%
Feb 2026
$0.01
$0.01
-63.89%
Oct 2025
$0.04
$0.04
+80.00%
Aug 2025
$0.03
$0.02
-33.33%
Jul 2025
$0.04
$0.03
-31.82%
Jun 2025
$0.01
$0.04
+300.00%
May 2025
$0.01
$0.01
+0.00%
Apr 2025
$0.01
$0.01
+0.00%

Apollomics Share Price FAQs